AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2018
Feb 12, 2018
29821_dirs_2018-02-12_fd200a93-b898-4b36-a196-7e45f4044086.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2018-02-09
Reporting Person: Nanavaty Maulik (SVP & Pres, Neuromodulation)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-02-09 | Common Stock | M | 15568.0000 | $12.5200 | Acquired | 229757.0000 | Direct |
| 2018-02-09 | Common Stock | S | 15568.0000 | $25.3798 | Disposed | 214189.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-09 | Stock Option (Right to Buy) | $12.5200 | M | 15568.0000 | Disposed | 2018-02-12 | Common Stock (15568.0000) | Direct |
Footnotes
F1: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.37 to $25.392, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Grant to the reporting person of an option to purchase 25,568 shares of common stock vesting in four annual increments beginning on February 12, 2009, the first anniversary of the grant.